Laser Focused on Revolutionizing
Vitreoretinal Treatments
The Problem
Over 500 Million People Suffer From Eye Disease
Diseases such as age-related macular degeneration (AMD), diabetic retinopathy, branch retinal vein occlusion, vitreomacular traction, and glaucoma affect hundreds of millions of people worldwide. While some of these conditions don't have an effective treatment option, others require monthly eye injections to reduce disease progression.
Our Solution
PulseMedica is developing a medical device platform that enables safe, effective and non-invasive treatment of various eye diseases. Our platform leverages advanced imaging technology, embedded machine learning and laser technology to precisely diagnose, plan and treat diseased areas within the eye. Our platform will revolutionize existing treatments for eye diseases while also unlocking novel treatment options that currently do not exist.
Recent News
By Optics.org
April 4, 2022
PulseMedica closes $2.6M seed round
Early-stage financing for Canadian startup developing ultrafast laser treatment of several eye diseases.
By Taproot Edmonton
March 30, 2022
PulseMedica raises $2.6M as it prepares to launch laser treatment trial
PulseMedica has raised an oversubscribed $2.6-million seed round, which it largely plans to use to run its first clinical trial beginning in June. The University of Alberta spinoff company is working on a new way to treat patients with major eye diseases.
By Ophthalmology Innovation Source
February 2, 2022
A Laser-Focused Business Model, with Nir Katchinskiy, PhD and Lahav Gil
The OIS podcast features leaders and drivers of ophthalmic innovation from around the world. In January 2022, PulseMedica’s CEO Nir Katchinskiy and Advisor Lahav Gil joined Dr. Ehsan Sadri MD FACS on the Ophthalmology Innovation Source (OIS) podcast.